61241-07-4

Basic information

• Product Name: 4-NITRO-1H-PYRAZOLE-3-CARBONITRILE
• Synonyms: ART-CHEM-BB B019523;1H-PYRAZOLE-3-CARBONITRILE, 4-NITRO-;AKOS B019523;4-NITRO-1H-PYRAZOLE-3-CARBONITRILE;NSC360638;1H-Pyrazole-3-carbonitrile,4-nitro-(9CI);4-nitro-1H-pyrazole-5-carbonitrile;4-nitro-2H-pyrazole-3-carbonitrile
• CAS NO: 61241-07-4
• Molecular Formula: C₄H₂N₄O₂
• Molecular Weight: 138.08
• Product Categories: NITRO
• Mol File: 61241-07-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 468.3 °C at 760 mmHg
• Flash Point: 237 °C
• Appearance: /
• Density: 1.63 g/cm³
• Vapor Pressure: 6.08E-09mmHg at 25°C
• Refractive Index: 1.602
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-NITRO-1H-PYRAZOLE-3-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-NITRO-1H-PYRAZOLE-3-CARBONITRILE(61241-07-4)
• EPA Substance Registry System: 4-NITRO-1H-PYRAZOLE-3-CARBONITRILE(61241-07-4)

Safety Data

• Hazardous Substances Data: 61241-07-4(Hazardous Substances Data)

Usage

General Description

4-Nitro-1H-pyrazole-3-carbonitrile is a chemical compound with the molecular formula C4H2N4O2. It is a yellow solid and has the CAS number 85913-36-2. 4-NITRO-1H-PYRAZOLE-3-CARBONITRILE is a pyrazole derivative and contains both a nitro group and a cyano group, making it useful for various synthetic and pharmaceutical applications. It is commonly used as a building block in the synthesis of heterocyclic compounds and pharmaceutical intermediates. Its diverse reactivity and functional groups make it a valuable tool in the development of new chemical compounds and drugs. Additionally, its unique structural properties make it a potentially valuable candidate for further research and development in the field of organic chemistry.

InChI:InChI=1/C4H2N4O2/c5-1-3-4(8(9)10)2-6-7-3/h2H,(H,6,7)

Upstream product

• 65190-36-5 4-nitro-1H-pyrazole-3-carboxamide 
• 65190-36-5 4-nitro-1H-pyrazole-5-carboxamide 

Downstream Products

• 13877-56-0 7-aminopyrazolo<4,3-d>pyrimidine 
• 68703-67-3 4-amino-1H-pyrazole-5-carbonitrile 
• 1094739-82-8 1-(2-bromo-3,4,5-trimethoxybenzyl)-4-nitro-1H-pyrazole-3-carbonitrile 
• 1426541-58-3 4-nitro-1-phenyl-1H-pyrazole-3-carbonitrile 
• 68703-67-3 4-amino-1H-pyrazole-3-carbonitrile 
• 151599-40-5 1-methyl-4-nitro-1H-pyrazole-3-carbonitrile 

Relevant articles and documents

Design, synthesis, and cytotoxic activity of novel 2H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidine derivatives

In this study, a series of novel 2H-imidazo [1, 2-c] pyrazolo [3, 4-e] pyrimidine derivatives were designed, synthesized, and evaluated for their cytotoxic activities. The in vitro cell growth inhibition assay of the target compounds indicated their selectivity in inhibiting the proliferation of blood tumor cells (K562, U937) and solid tumor cells (HCT116, HT-29). Compound 9b exhibited the highest antiproliferative activities against K562 (IC50 = 5.597 μM) and U937 (IC50 = 3.512 μM). Based on the flow cytometry assays, compound 9b caused obvious induction of cell apoptosis and cell arrest at the S phase. Furthermore, western blot analysis revealed that compound 9b upregulated the expression of Bax, downregulated the levels of Bcl-2, and further activated caspase-3 in K562 cells. Therefore, compound 9b may be a potential anticancer agent that deserves further investigation.

ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF

An ALK kinase inhibitor compound as represented by Formula I, pharmaceutical composition containing the compound, and preparation method and use thereof in the preparation of drugs serving as an ALK inhibitor for treating cancer.

Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors

Anaplastic lymphoma kinase (ALK) is a highly attractive therapeutic target for the treatment of some non-small cell lung cancer patients. This Letter describes the further SAR exploration on the novel 3-sulfonylpyrazol-4-amino pyrimidine scaffold. This work identified a compound 53 with very good in vitro/in vivo efficacies, good DMPK properties together with better hERG tolerability and it is currently being profiled for the evaluation as a potential pre-clinical candidate.